Concepedia

Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome

Kehinde S. Olaniyi, Stephanie E. Areloegbe, Emmanuel Damilare Areola, Isaiah Woru Sabinari, Adedamola Adediran Fafure, Richard Dele Agbana, Chukwubueze L. Atuma, Mohd Zahoor ul haq Shah, Isaac O. Ajadi, Lawrence A. Olatunji

Toxicology and Applied Pharmacology · 2023 · 10 citations · 15 references

DOI

Concepts

References

15

Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease

Hasan Kafalı, Mehmet İriadam, İlyas Özardalı et al. · Archives of Medical Research · 2004 · 447 citations

, , +16

Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China

Xiaowei Zhu, Lugang Yu, Hui Zhou et al. · Lipids in Health and Disease · 2018 · 247 citations · Full text

, , +13

Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome

Meijiao Wang, Dan Zhao, Liangzhi Xu et al. · Metabolism · 2019 · 104 citations

, , +16

Innovative Use of Spironolactone as an Antiandrogen in the Treatment of Female Pattern Hair Loss

Deepani Rathnayake, Rodney Sinclair · Dermatologic Clinics · 2010 · 85 citations

, , +9

Polycystic ovaries are a common finding in untreated female to male transsexuals

Adam Balen, Morey Schachter, Don Montgomery et al. · Clinical Endocrinology · 1993 · 76 citations

, , +11